GlassScriptPhysician profile
Jose Tamayo
NPI 1912161340
$2,517.00
in general payments reported to CMS, 2019-2025
33 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $487 · 2021: $496 · 2022: $285 · 2023: $325 · 2024: $432 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.64 | 2019-2025 | Tradjenta, Jardiance, Ofev |
| Novo Nordisk INC | $289.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $186.85 | 2019-2023 | |
| Exact Sciences Corporation | $163.83 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $130.69 | 2019-2023 | Breztri |
| Sanofi-Aventis U.S. LLC | $127.02 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $98.01 | 2021 | |
| Merck Sharp & Dohme LLC | $87.82 | 2019-2021 | |
| Lilly USA, LLC | $70.65 | 2020-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $65.26 | 2020-2021 | |
| Dynavax Technologies Corporation | $63.35 | 2024-2025 | Heplisav-B |
| Boston Scientific Corporation | $59.51 | 2024-2025 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.71 | 2019-2022 | |
| Daiichi Sankyo INC. | $55.53 | 2021-2022 | |
| Astellas Pharma US INC | $54.99 | 2019-2025 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.09 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $51.73 | 2019-2021 | |
| Abbvie INC. | $46.00 | 2021 | |
| Eisai INC. | $42.35 | 2020-2021 | |
| Ibsa Pharma INC. | $32.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.24 | 2023 | |
| Janssen Pharmaceuticals, INC | $29.65 | 2020 | |
| Glaxosmithkline, LLC. | $27.48 | 2019-2022 | |
| Radius Health, INC. | $27.41 | 2020 | |
| Allergan, INC. | $26.93 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $24.50 | 2023 | Nuedexta |
| Sumitomo Pharma America, INC. | $24.25 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $19.95 | 2020 | |
| Inspire Medical Systems, INC. | $17.30 | 2024 | Inspire |
| Amgen INC. | $17.02 | 2024 | Repatha, Otezla |
| Adlon Therapeutics L.P. | $16.67 | 2020 | |
| Shield Therapeutics INC | $15.02 | 2022 | |
| Endo Pharmaceuticals INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Tamayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.